Evidence indicates that diet, nutrition, lifestyle, the environment, the microbiome, and other
exogenous factors have pathogenic roles and also influence the genome, epigenome …

Significant progress in the development of new immunotherapies has led to successful
clinical trials for malignant melanoma and non-small cell lung cancer; however, for the …

Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced
hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug …

The organometallic ruthenium (II)[Ru (arene) Cl2PTA] PTA‐1, 3, 5‐triaza‐7‐
phosphaadamantane compound, RAPTA‐C, represents an innovative anti‐cancer …

In the last few years, the treatment strategy in Non-Small Cell Lung Cancer (NSCLC)
patients has been heavily modified by the introduction of the immune-checkpoint inhibitors …

Hepatocellular carcinoma is the most common primary liver cancer and the fourth leading
cause of cancer death worldwide. A total of 70–80% of patients are diagnosed at an …

Gastrointestinal (GI) cancer is a malignancy of the GI tract and accessory digestive organs.
GI cancer patients develop resistance to chemotherapy, targeted therapy drugs and immune …

Despite significant progress in our understanding of the etiology, biology and genetics of
colorectal cancer, as well as important clinical advances, it remains the third most frequently …

Background Evidence indicates not only carcinogenic effect of cigarette smoking but also its
immunosuppressive effect. We hypothesized that the association of smoking with colorectal …

Immunotherapy by using immune checkpoint inhibitors (ICI) has dramatically improved the
treatment options in various cancers, increasing survival rates for treated patients …